hy-n2098 Search Results


obtusifolin  (MedChemExpress)
94
MedChemExpress obtusifolin
A: Obtusifolins chemical structure; B: Representative rat eye images after topic administration of <t>obtusifolin</t> for 4d; C: Conjunctival irritation score in each group (Sham+DMSO and Sham+Obtusifolin groups had scores of 0, overlapping with the x-axis); D: Evaluation of tear secretion in each group ( n =8). a P <0.05, b P <0.01. DED: Dry eye disease; DMSO: Dimethyl sulfoxide.
Obtusifolin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-n2098/Obtusifolin/pmc12311460-15-0-13
Average 94 stars, based on 1 article reviews
obtusifolin - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


A: Obtusifolins chemical structure; B: Representative rat eye images after topic administration of obtusifolin for 4d; C: Conjunctival irritation score in each group (Sham+DMSO and Sham+Obtusifolin groups had scores of 0, overlapping with the x-axis); D: Evaluation of tear secretion in each group ( n =8). a P <0.05, b P <0.01. DED: Dry eye disease; DMSO: Dimethyl sulfoxide.

Journal: International Journal of Ophthalmology

Article Title: Obtusifolin ameliorates dry eye model in rats by reducing inflammation and blocking MAPK/NF-κB pathways

doi: 10.18240/ijo.2025.08.02

Figure Lengend Snippet: A: Obtusifolins chemical structure; B: Representative rat eye images after topic administration of obtusifolin for 4d; C: Conjunctival irritation score in each group (Sham+DMSO and Sham+Obtusifolin groups had scores of 0, overlapping with the x-axis); D: Evaluation of tear secretion in each group ( n =8). a P <0.05, b P <0.01. DED: Dry eye disease; DMSO: Dimethyl sulfoxide.

Article Snippet: Obtusifolin (99.8% purity, HY-N2098) and BAC solution (≥98.0% purity, HY-B2232) were obtained from MedChemExpress (Shanghai, China).

Techniques:

A-D: Measurement of the concentrations of inflammatory mediators in the conjunctiva of rats using ELISA kits ( n =8); E: Representative conjunctival PAS staining images in each group; F: Quantification of goblet cell numbers in the conjunctiva ( n =4). b P <0.01, c P <0.001 vs Sham+DMSO group; d P <0.01 vs DED+DMSO group. BAC: Benzalkonium chloride; ELISA: Enzyme-linked immunosorbent assay; PAS: Periodic acid-Schiff; DED: Dry eye disease; DMSO: Dimethyl sulfoxide.

Journal: International Journal of Ophthalmology

Article Title: Obtusifolin ameliorates dry eye model in rats by reducing inflammation and blocking MAPK/NF-κB pathways

doi: 10.18240/ijo.2025.08.02

Figure Lengend Snippet: A-D: Measurement of the concentrations of inflammatory mediators in the conjunctiva of rats using ELISA kits ( n =8); E: Representative conjunctival PAS staining images in each group; F: Quantification of goblet cell numbers in the conjunctiva ( n =4). b P <0.01, c P <0.001 vs Sham+DMSO group; d P <0.01 vs DED+DMSO group. BAC: Benzalkonium chloride; ELISA: Enzyme-linked immunosorbent assay; PAS: Periodic acid-Schiff; DED: Dry eye disease; DMSO: Dimethyl sulfoxide.

Article Snippet: Obtusifolin (99.8% purity, HY-N2098) and BAC solution (≥98.0% purity, HY-B2232) were obtained from MedChemExpress (Shanghai, China).

Techniques: Enzyme-linked Immunosorbent Assay, Staining

A: Representative images of corneal fluorescein staining for estimating corneal epithelial damage of rats after treatment with obtusifolin for 4d; B: Assessment of corneal fluorescein staining scores in each group ( n =8); C: Western blotting for evaluating ZO-1 and MMP-9 protein expression in the cornea of rats; D-E: Quantification of protein levels ( n =4). c P <0.001 vs Sham+DMSO group; d P <0.01, e P <0.001 vs DED+DMSO group. DED: Dry eye disease; ZO-1: Zonula occludens-1; MMP-9: Matrix metalloproteinase-9; DMSO: Dimethyl sulfoxide.

Journal: International Journal of Ophthalmology

Article Title: Obtusifolin ameliorates dry eye model in rats by reducing inflammation and blocking MAPK/NF-κB pathways

doi: 10.18240/ijo.2025.08.02

Figure Lengend Snippet: A: Representative images of corneal fluorescein staining for estimating corneal epithelial damage of rats after treatment with obtusifolin for 4d; B: Assessment of corneal fluorescein staining scores in each group ( n =8); C: Western blotting for evaluating ZO-1 and MMP-9 protein expression in the cornea of rats; D-E: Quantification of protein levels ( n =4). c P <0.001 vs Sham+DMSO group; d P <0.01, e P <0.001 vs DED+DMSO group. DED: Dry eye disease; ZO-1: Zonula occludens-1; MMP-9: Matrix metalloproteinase-9; DMSO: Dimethyl sulfoxide.

Article Snippet: Obtusifolin (99.8% purity, HY-N2098) and BAC solution (≥98.0% purity, HY-B2232) were obtained from MedChemExpress (Shanghai, China).

Techniques: Disruption, Staining, Western Blot, Expressing

A: Western blotting for assessing expression of MAPK/NF-κB signaling-related proteins in the conjunctiva of rats; B: Quantification of relative protein expression. n =4. c P <0.001 vs Sham+DMSO group; f P <0.05 vs DED+DMSO group. MAPK: Mitogen-activated protein kinase; NF-κB: Nuclear factor kappa B; DED: Dry eye disease; DMSO: Dimethyl sulfoxide.

Journal: International Journal of Ophthalmology

Article Title: Obtusifolin ameliorates dry eye model in rats by reducing inflammation and blocking MAPK/NF-κB pathways

doi: 10.18240/ijo.2025.08.02

Figure Lengend Snippet: A: Western blotting for assessing expression of MAPK/NF-κB signaling-related proteins in the conjunctiva of rats; B: Quantification of relative protein expression. n =4. c P <0.001 vs Sham+DMSO group; f P <0.05 vs DED+DMSO group. MAPK: Mitogen-activated protein kinase; NF-κB: Nuclear factor kappa B; DED: Dry eye disease; DMSO: Dimethyl sulfoxide.

Article Snippet: Obtusifolin (99.8% purity, HY-N2098) and BAC solution (≥98.0% purity, HY-B2232) were obtained from MedChemExpress (Shanghai, China).

Techniques: Western Blot, Expressing